早産とPROM検査の市場：タイプ、サンプル、エンドユーザー別-2025-2030年の世界予測

早産とPROM検査市場の2023年の市場規模は15億5,000万米ドルで、2024年には16億4,000万米ドルに成長し、CAGRは6.20%、2030年には23億6,000万米ドルに達すると予測されています。

エグゼクティブサマリー導入：早産とPROM検査の舞台設定

急速に進化する今日のヘルスケア環境において、早産とPROM（膜早期破裂）の早期発見と管理は、臨床医、研究者、意思決定者にとって重要な焦点となっています。本レポートは、診断および予後検査アプローチの複雑な状況を掘り下げ、患者ケアを形成する従来の方法論と新たな方法論の両方に光を当てています。イントロダクションでは、早期発見とタイムリーな介入が臨床的にいかに重要であるかを探求し、先進的な検査技術が新生児の転帰改善にいかに貢献し、関連する健康リスクをいかに軽減するかを強調しています。ここで提供される包括的な洞察を通して、読者は、技術革新、規制状況の変化、そして進化する臨床実践が、早産とPROM検査の情勢をどのように変化させつつあるのかについて理解を深めることができます。本レポートは、データ主導の分析と実用的な情報に重点を置き、臨床プロトコールと診断精度を再定義する可能性のある動向を特定するために、強力な市場調査を活用しています。現状と今後の動向について全体的な視点を確立することで、患者管理戦略の最適化と標準治療の推進を目指す業界専門家と主要な意思決定者の双方に適した内容となっています。

情勢の転換：早産とPROM検査における革新と進化する実践

早産とPROM検査の情勢は、革新的な診断技術と進化する臨床実践に後押しされ、変革の時を迎えています。近年、改良された画像診断技術や生化学的検査と高度な診断ツールの統合により、早産に関連するリスクの検出率や特定精度が大幅に向上しています。研究のブレークスルーと学際的な共同研究に後押しされ、臨床医は新規バイオマーカーやより精密なスクリーニング検査を日常診療に取り入れるようになってきています。さらに、さまざまな地域の規制機関は、こうした技術的進歩に対応するためにガイドラインを更新し、革新的な検査法の迅速な採用を促す環境を醸成しています。その結果、ヘルスケア全般にわたる利害関係者は、検査の感度と特異度が加速度的に向上し、患者の転帰改善につながることを目の当たりにしています。さらに、デジタルヘルスソリューションとリアルタイムデータ解析の融合により、医療従事者は迅速かつ十分な情報に基づいた意思決定を行うことができるようになり、早期診断の価値が高まっています。このような変革は、早産やPROMに関連する罹患率や死亡率の低減へのコミットメントを反映していると同時に、個別化された予測的ヘルスケア介入への新たな道を開くものでもあります。

主要セグメントに関する洞察検査における診断モダリティとサンプルタイプの詳細

当社の分析では、市場の構造と進化をより明確に示す、明確なセグメンテーション動向を明らかにしています。市場情勢をタイプ別に検討すると、生化学マーカー、フェルニングテスト、胎児フィブロネクチン、ニタジンテスト、骨盤内検査、プーリング、超音波検査、子宮モニタリングなど、一連の診断様式で市場が評価されます。特に注目すべきは生化学マーカーで、α-フェトプロテイン、C反応性タンパク質、コルチコトロピン放出ホルモン、IL-1、IL-2、IL-8、TNF-a、インスリン様成長因子結合タンパク質-1、インターロイキン（IL）-6、胎盤αミクログロブリン-1など、いくつかのサブカテゴリーにさらに分類されています。技術ベースのセグメンテーションに加え、羊水、血液、尿、膣分泌液から得られた診断用サンプルに焦点を当てたサンプルベースのセグメンテーションも考慮しています。さらに、重要なエンドユーザーセグメンテーションでは、市場を診断ラボ、病院・診療所、専門センターに区分しています。これらのセグメンテーションの洞察は、現在の市場動向の促進要因を形成している様々な検査アプローチ、サンプルソース、アプリケーション設定の複雑さと相互関連性を強調しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病と高血圧の増加による早産の蔓延
    • ポイントオブケア検査ソリューションの開発への注目が高まる
    • 早産率の削減を目指す政府とヘルスケアの取り組みの拡大
  • 抑制要因
    • PROM検査の偽陽性結果に対する懸念の高まり
  • 機会
    • 早産とPROM検査ソリューション開発への企業による投資増加
    • PROMテストの研究開発活動における新たな共同の取り組み
  • 課題
    • 早産およびPROM検査に関する厳格な規制とさまざまな承認プロセス
• 市場セグメンテーション分析
  • タイプ：早産およびPROMの早期発見と管理のための生化学マーカーの使用増加
  • サンプル：高い特異性と感度により、臨床現場での羊水検査の利用が拡大
  • エンドユーザー：精度と大量検査により、診断検査室での早産およびPROM検査の利用が増加している
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 早産とPROM検査の市場：タイプ別

• 生化学マーカー
  • アルファフェトプロテイン
  • C反応性タンパク質
  • 副腎皮質刺激ホルモン放出ホルモン
  • IL-1、IL-2、IL-8、TNF-α
  • インスリン様成長因子結合タンパク質-1
  • インターロイキン（IL）-6
  • 胎盤αミクログロブリン-1
• シダ試験
• 胎児フィブロネクチン
• ニタジンテスト
• 骨盤検査
• プーリング
• 超音波
• 子宮モニタリング

第7章 早産とPROM検査の市場サンプル別

• 羊水
• 血
• 尿
• 膣分泌物

第8章 早産とPROM検査の市場：エンドユーザー別

• 診断検査室
• 病院と診療所
• 専門センター

第9章 南北アメリカの早産とPROM検査の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の早産とPROM検査の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの早産とPROM検査の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• BillionToOne, Inc.
• Biosynex SA
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• FUJIFILM Holdings Corporation
• GE HealthCare Technologies, Inc.
• Hologic, Inc.
• Igenomix India Private Limited
• Illumina, Inc.
• Koninklijke Philips N.V.
• Laboratory Corporation of America Holdings
• Medix Biochemica Group
• Nanjing Liming Bio-products Co., Ltd.
• Natera, Inc.
• NX Prenatal, Inc.
• Pro Lab Diagnostics Inc
• Qiagen N.V.
• Revvity, Inc.
• Samsung Electronics Co., Ltd.
• Sekisui Diagnostics, LLC
• Sera prognostics, Inc.
• Siemens Healthineers AG
• The Cooper Companies, Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. PRETERM BIRTH & PROM TESTING MARKET MULTI-CURRENCY
• FIGURE 2. PRETERM BIRTH & PROM TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. PRETERM BIRTH & PROM TESTING MARKET RESEARCH PROCESS
• FIGURE 4. PRETERM BIRTH & PROM TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PRETERM BIRTH & PROM TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRETERM BIRTH & PROM TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ALPHA-FETOPROTEIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY CORTICOTROPIN-RELEASING HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IL-1, IL-2, IL-8, TNF-A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INTERLEUKIN (IL)-6, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PLACENTAL ALPHA MICROGLOBULIN-1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY FERNING TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY FETAL FIBRONECTIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY NITAZINE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PELVIC EXAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY POOLING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY UTERINE MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY VAGINAL SECRETIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 70. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 74. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 143. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 144. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 159. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 160. POLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 163. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 164. QATAR PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL MARKERS, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 202. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Preterm Birth & PROM Testing Market was valued at USD 1.55 billion in 2023 and is projected to grow to USD 1.64 billion in 2024, with a CAGR of 6.20%, reaching USD 2.36 billion by 2030.

Executive Summary Introduction: Setting the Stage for Preterm Birth & PROM Testing

In today's rapidly evolving healthcare environment, the early detection and management of preterm birth and PROM (premature rupture of membranes) have emerged as critical focal points for clinicians, researchers, and decision-makers alike. This report delves into the intricate landscape of diagnostic and prognostic testing approaches, shedding light on both traditional and emerging methodologies that shape patient care. The introduction explores the clinical importance of early detection and timely intervention, underlining how advanced testing techniques contribute to better neonatal outcomes and reduce associated health risks. As we navigate through the comprehensive insights provided herein, the reader will develop an understanding of how technological innovations, regulatory shifts, and evolving clinical practices are converging to transform the landscape of preterm birth and PROM testing. Emphasizing data-driven analysis and actionable intelligence, this report leverages robust market research to identify trends that have the potential to redefine clinical protocols and diagnostic accuracy. By establishing a holistic view of the current state and prospective trends, the content is tailored to both industry experts and key decision-makers seeking to optimize patient management strategies and drive forward the standards of care.

Transformative Shifts in the Landscape: Innovations and Evolving Practices in Preterm Birth & PROM Testing

The landscape of preterm birth and PROM testing is undergoing transformative shifts fueled by innovative diagnostic technologies and evolving clinical practices. Over recent years, the integration of advanced diagnostic tools with improved imaging techniques and biochemical testing has significantly enhanced the detection rates and accuracy of identifying risks associated with premature birth. Driven by research breakthroughs and cross-disciplinary collaborations, clinicians are increasingly incorporating novel biomarkers and more precise screening tests into routine practice. Moreover, regulatory bodies across various geographies have updated guidelines to accommodate these technological advances, fostering an environment that encourages rapid adoption of innovative testing methods. As a consequence, stakeholders across the healthcare continuum are witnessing accelerated developments in test sensitivity and specificity, leading to improved patient outcomes. Additionally, the convergence of digital health solutions and real-time data analytics has enabled practitioners to make swift, informed decisions, thereby reinforcing the value of early diagnostics. These transformative shifts collectively reflect a commitment to reducing the morbidity and mortality associated with preterm birth and PROM, while also opening new avenues for personalized and predictive healthcare interventions.

Key Segmentation Insights: A Detailed Look into Diagnostic Modalities and Sample Types in Testing

Our analysis identifies distinct segmentation trends that provide a clearer picture of the market's structure and evolution. When examining the landscape based on type, the market is evaluated across an array of diagnostic modalities including biochemical markers, the ferning test, fetal fibronectin, the nitazine test, pelvic exam, pooling, ultrasound, and uterine monitoring. Of particular note are biochemical markers, which have been further dissected into several sub-categories such as alpha-fetoprotein, C-reactive protein, corticotropin-releasing hormone, IL-1, IL-2, IL-8, TNF-a, insulin-like growth factor binding protein-1, interleukin (IL)-6, and placental alpha microglobulin-1. In addition to the technology-based segmentation, the analysis also considers sample-based divisions, focusing on diagnostic samples derived from amniotic fluid, blood, urine, and vaginal secretions, each of which provides unique insights into the diagnostic process. Furthermore, a critical end-user segmentation delineates the market into diagnostic laboratories, hospitals and clinics, and specialty centers. These segmentation insights collectively underscore the complexity and interconnectivity of the various testing approaches, sample sources, and application settings that are coalescing to form the drivers of current market trends.

Based on Type, market is studied across Biochemical Markers, Ferning Test, Fetal Fibronectin, Nitazine Test, Pelvic exam, Pooling, Ultrasound, and Uterine Monitoring. The Biochemical Markers is further studied across Alpha-fetoprotein, C-Reactive Protein, Corticotropin-Releasing Hormone, IL-1, IL-2, IL-8, TNF-a, Insulin-like Growth Factor Binding Protein-1, Interleukin (IL)-6, and Placental Alpha Microglobulin-1.

Based on Sample, market is studied across Amniotic Fluid, Blood, Urine, and Vaginal Secretions.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Specialty Centers.

Key Regional Insights: Understanding Market Dynamics Across Global Territories

Regional dynamics play an essential role in shaping the market trends for preterm birth and PROM testing. The market reveals distinct characteristics and varying rates of adoption across different geographies. In the Americas, strong investments in healthcare technologies, coupled with advanced infrastructure, have positioned the region at the forefront of testing innovations. Regions encompassing Europe, the Middle East, and Africa exhibit a wide spectrum of market maturity, where the interplay of established healthcare systems and emerging economies stimulates both sophisticated testing advancements and rapid adoption of novel diagnostics. In Asia-Pacific, rising healthcare expenditure and a burgeoning patient population are driving the rapid integration of state-of-the-art diagnostics into clinical practice. These developments are further boosted by regional government initiatives focused on enhancing maternal and neonatal health outcomes. Collectively, these regional insights highlight the need for tailored market strategies that account for varying economic landscapes, regulatory environments, and cultural factors, which in turn dictate the pace at which testing methodologies are embraced and implemented.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leading Innovators and Market Influencers in Diagnostic Testing

The market for preterm birth and PROM testing is increasingly competitive, with several leading companies driving innovation and shaping market dynamics. Industry leaders such as Abbott Laboratories, BillionToOne, Inc., Biosynex SA, Eurofins Scientific SE, and F. Hoffmann-La Roche AG have consistently pushed the boundaries in diagnostic accuracy and test efficacy. These companies are complemented by organizations like FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., and Hologic, Inc., whose contributions in imaging and analytical solutions are pivotal in refining test protocols. Further notable players include Igenomix India Private Limited, Illumina, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, and Medix Biochemica Group, all of which emphasize the importance of robust technology integration. Leaders like Nanjing Liming Bio-products Co., Ltd., Natera, Inc., NX Prenatal, Inc., Pro Lab Diagnostics Inc, and Qiagen N.V. are continuously evolving to meet clinical demands. Additional contributions from Revvity, Inc., Samsung Electronics Co., Ltd., Sekisui Diagnostics, LLC, Sera Prognostics, Inc., Siemens Healthineers AG, The Cooper Companies, Inc., and Thermo Fisher Scientific Inc. further underscore the multi-faceted competitive landscape. This competitive milieu reflects a relentless pursuit of innovation, improved patient outcomes, and operational excellence in diagnostic testing.

The report delves into recent significant developments in the Preterm Birth & PROM Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BillionToOne, Inc., Biosynex SA, Eurofins Scientific SE, F. Hoffmann-La Roche AG, FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Igenomix India Private Limited, Illumina, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medix Biochemica Group, Nanjing Liming Bio-products Co., Ltd., Natera, Inc., NX Prenatal, Inc., Pro Lab Diagnostics Inc, Qiagen N.V., Revvity, Inc., Samsung Electronics Co., Ltd., Sekisui Diagnostics, LLC, Sera prognostics, Inc., Siemens Healthineers AG, The Cooper Companies, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders: Strategies to Enhance Diagnostic Value and Market Positioning

Industry leaders are encouraged to adopt proactive and innovative strategies to maintain competitive advantage in the dynamic market of preterm birth and PROM testing. Embracing technology-driven advancements is imperative in today's clinical environment. Companies should invest in continuous research and development to explore novel biomarkers and testing methodologies, ensuring that new diagnostic solutions anticipate future clinical needs. Furthermore, strategic collaborations with academic institutions and healthcare providers can expedite the translation of cutting-edge research into reliable, market-ready solutions. Emphasis should be placed on integrating digital health platforms and real-time data analytics not only to improve test turnaround times but also to enhance predictive accuracy through personalized patient profiles. In addition, expanding geographical reach into regions with emerging markets can create new revenue channels while addressing unmet clinical needs. Cost-effective operational strategies, coupled with a robust regulatory compliance framework, will aid in ensuring that testing solutions remain accessible and trustworthy. Ultimately, leaders must balance rapid innovation with patient safety and data integrity, fostering a culture of excellence that positions their organizations as pioneers in the field of preterm birth and PROM testing.

Conclusion: Synthesizing Insights to Shape the Future of Diagnostic Testing in Preterm Birth and PROM

The comprehensive insights presented in this report underscore the multifaceted nature of the preterm birth and PROM testing market. From transformative technological shifts to detailed segmentation analyses and regional dynamics, it becomes clear that the landscape is marked by both complexity and opportunity. Integrating advanced diagnostic tools with refined clinical practices has paved the way for improved patient care and better outcomes in maternal and neonatal health. As the market continues to evolve, the interplay between innovative testing methodologies and strategic industry positioning will be fundamental to driving progress and addressing unmet clinical needs. This synthesis of data, trends, and actionable strategies offers a clear vision for the future, emphasizing the importance of agility, sustained investment in research, and cross-industry partnerships. Ultimately, the shared goal remains to enhance diagnostic precision, thereby contributing to more informed decision-making and improved quality of care for patients globally.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of preterm births owing to the increasing rates of diabetes and hypertension
    • 5.1.1.2. Rising focus on the development of point-of-care testing solutions
    • 5.1.1.3. Growing government and healthcare initiatives aimed at reducing preterm birth rates
  • 5.1.2. Restraints
    • 5.1.2.1. Rising concerns about false positive results of PROM tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising investment by companies for the development of preterm birth & PROM testing solutions
    • 5.1.3.2. Emerging collaborative efforts in research and development activities for PROM tests
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and varying approval processes for preterm birth & PROM tests
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing use of biochemical markers for early detection and management of preterm birth & PROM
  • 5.2.2. Sample: Expanding the use of amniotic fluid testing in clinical settings owing to high specificity and sensitivity
  • 5.2.3. End-User: Growing use of preterm birth & PROM tests in diagnostic laboratories owing to accuracy and mass testing
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preterm Birth & PROM Testing Market, by Type

• 6.1. Introduction
• 6.2. Biochemical Markers
  • 6.2.1. Alpha-fetoprotein
  • 6.2.2. C-Reactive Protein
  • 6.2.3. Corticotropin-Releasing Hormone
  • 6.2.4. IL-1, IL-2, IL-8, TNF-a
  • 6.2.5. Insulin-like Growth Factor Binding Protein-1
  • 6.2.6. Interleukin (IL)-6
  • 6.2.7. Placental Alpha Microglobulin-1
• 6.3. Ferning Test
• 6.4. Fetal Fibronectin
• 6.5. Nitazine Test
• 6.6. Pelvic exam
• 6.7. Pooling
• 6.8. Ultrasound
• 6.9. Uterine Monitoring

7. Preterm Birth & PROM Testing Market, by Sample

• 7.1. Introduction
• 7.2. Amniotic Fluid
• 7.3. Blood
• 7.4. Urine
• 7.5. Vaginal Secretions

8. Preterm Birth & PROM Testing Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals & Clinics
• 8.4. Specialty Centers

9. Americas Preterm Birth & PROM Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Preterm Birth & PROM Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Preterm Birth & PROM Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Novocuff Inc. secures USD 26 million in Series A funding to advance pioneering device addressing preterm birth and PROM with global impact
  • 12.3.2. Clarius Mobile Health's FDA-cleared Clarius OB AI tool enhances prenatal care with automated fetal biometry in the U.S. and Canada
  • 12.3.3. Lumos Diagnostics secures an additional USD 5 million from Hologic to enhance preterm birth diagnostics with advanced fetal fibronectin test
  • 12.3.4. Samsung Medison acquires Sonio SAS to integrate advanced AI technologies with ultrasound systems
  • 12.3.5. Natera Inc. unveils revolutionary cell-free DNA RhD test improving RhD-negative pregnancy care and conserving RhIg resources
  • 12.3.6. Revvity unveils NGS panel workflow to enhance newborn screening capabilities
  • 12.3.7. BillionToOne launches a new non-invasive prenatal test for preterm birth risk and PROM testing
  • 12.3.8. Cord Blood Registry (CBR) and Fulgent Genetics introduce advanced genetic testing services
  • 12.3.9. Bloomlife and PeriGen collaborate to address maternal and fetal health needs in underserved regions
  • 12.3.10. BillionToOne and Janssen collaborate on phase 3 AZALEA clinical trial of nipocalimab for HDFN
  • 12.3.11. Hologic collaborates with AAGL and Inovus Medical to advance OB-GYN training with advanced simulation technology
  • 12.3.12. GE HealthCare receives USD 44 million Gates Foundation grant to develop AI-assisted ultrasound for improving maternal and child healthcare in low-and-middle-income countries
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. Hologic, Inc.
  • 12.4.2. Laboratory Corporation of America Holdings
  • 12.4.3. Revvity, Inc.
  • 12.4.4. Siemens Healthineers AG

Companies Mentioned

• 1. Abbott Laboratories
• 2. BillionToOne, Inc.
• 3. Biosynex SA
• 4. Eurofins Scientific SE
• 5. F. Hoffmann-La Roche AG
• 6. FUJIFILM Holdings Corporation
• 7. GE HealthCare Technologies, Inc.
• 8. Hologic, Inc.
• 9. Igenomix India Private Limited
• 10. Illumina, Inc.
• 11. Koninklijke Philips N.V.
• 12. Laboratory Corporation of America Holdings
• 13. Medix Biochemica Group
• 14. Nanjing Liming Bio-products Co., Ltd.
• 15. Natera, Inc.
• 16. NX Prenatal, Inc.
• 17. Pro Lab Diagnostics Inc
• 18. Qiagen N.V.
• 19. Revvity, Inc.
• 20. Samsung Electronics Co., Ltd.
• 21. Sekisui Diagnostics, LLC
• 22. Sera prognostics, Inc.
• 23. Siemens Healthineers AG
• 24. The Cooper Companies, Inc.
• 25. Thermo Fisher Scientific Inc.